Patent intelligence · US
US 9040241
Genetic markers of mental illness
Genetic markers of mental illness
Patent details — US 9040241
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 26, 2015
- Expiration
- May 21, 2035
- Applicant
- SureGene LLC
- Claims
- 30
- CPC classes
- A61K, A61K31/496, A61K31/519, A61K31/5415
Quick answer
US 9040241 (Genetic markers of mental illness) is held by SureGene LLC. Status: granted. Granted May 26, 2015. Expires May 21, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- SureGene LLC
- Grant date
- Expiration
- Claims
- 30
- CPC classes
- A61K, A61K31/496, A61K31/519, A61K31/5415, A61K31/551, A61K31/5513
More from SureGene LLC
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 9040241?
US 9040241 (Genetic markers of mental illness) is held by SureGene LLC. Status: granted. Granted May 26, 2015. Expires May 21, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9040241?
SureGene LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 9040241 expire?
Our index shows an expiration date of May 21, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.